The new capital of SEK 26 million was invested by the Sciety syndicate, a leading investor in Nordic life science and digital health.
“Working with Sciety, we have not only received capital but also specialist expertise and a strong network of people in the industry. Sciety is an established investment player and an experienced and knowledgeable partner who can give us the best conditions to develop our products further and support us when our company expands,” says Encare’s CEO, Rasmus Waller.
Encare already has a large international customer base with more than 140 hospitals in 25 different countries, and data from Encare’s customers shows significant quality improvements and savings. This has resulted in great interest from all parts of the world.
Encare is now planning for a continued expansion to gain additional market share in the more than 17,000 emergency hospitals that perform advanced surgery in Europe and North America.
“With the new capital, we gain additional power to accelerate our international expansion and further strengthen our product development organisation,” says Rasmus Waller, CEO.
Every year around 300 million surgical procedures are carried out worldwide – but one in four patients suffers from complications. About half of these, 37 million, could be avoided. Complications resulting from various healthcare interventions are today a leading cause of death and entail high healthcare costs worldwide.
“We are very pleased to be able to help Encare on the way to their goal of minimising unnecessary complications that too many patients suffer after surgery, thereby reducing both suffering and costs. The company already has an international clientele and is on the threshold of even broader international expansion, which makes this an extra exciting investment,” says Andreas Lindblom, Managing Partner at Sciety.
Read more about Encare here